6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dopamine (DA) is one of the main neurotransmitters found in the central nervous system and has a vital role in the function of dopaminergic (DArgic) neurons. A progressive loss of this specific subset of cells is one of the hallmarks of age-related neurodegenerative disorders such as Parkinson’s disease (PD). Symptomatic therapy for PD has been centered in the precursor l-DOPA administration, an amino acid precursor of DA that crosses the blood–brain barrier (BBB) while DA does not, although this approach presents medium- to long-term side effects. To overcome this limitation, DA-nanoencapsulation therapies are actively being searched as an alternative for DA replacement. However, overcoming the low yield of encapsulation and/or poor biodistribution/bioavailability of DA is still a current challenge. Herein, we report the synthesis of a family of neuromelanin bioinspired polymeric nanoparticles. Our system is based on the encapsulation of DA within nanoparticles through its reversible coordination complexation to iron metal nodes polymerized with a bis-imidazol ligand. Our methodology, in addition to being simple and inexpensive, results in DA loading efficiencies of up to 60%. In vitro, DA nanoscale coordination polymers (DA-NCPs) exhibited lower toxicity, degradation kinetics, and enhanced uptake by BE(2)-M17 DArgic cells compared to free DA. Direct infusion of the particles in the ventricle of rats in vivo showed a rapid distribution within the brain of healthy rats, leading to an increase in striatal DA levels. More importantly, after 4 days of nasal administrations with DA-NCPs equivalent to 200 μg of the free drug per day, the number and duration of apomorphine-induced rotations was significantly lower from that in either vehicle or DA-treated rats performed for comparison purposes. Overall, this study demonstrates the advantages of using nanostructured DA for DA-replacement therapy.

          Related collections

          Most cited references90

          • Record: found
          • Abstract: found
          • Article: not found

          NIH Image to ImageJ: 25 years of image analysis

          For the past twenty five years the NIH family of imaging software, NIH Image and ImageJ have been pioneers as open tools for scientific image analysis. We discuss the origins, challenges and solutions of these two programs, and how their history can serve to advise and inform other software projects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Parkinson's disease.

            Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long been characterised by the classical motor features of parkinsonism associated with Lewy bodies and loss of dopaminergic neurons in the substantia nigra. However, the symptomatology of Parkinson's disease is now recognised as heterogeneous, with clinically significant non-motor features. Similarly, its pathology involves extensive regions of the nervous system, various neurotransmitters, and protein aggregates other than just Lewy bodies. The cause of Parkinson's disease remains unknown, but risk of developing Parkinson's disease is no longer viewed as primarily due to environmental factors. Instead, Parkinson's disease seems to result from a complicated interplay of genetic and environmental factors affecting numerous fundamental cellular processes. The complexity of Parkinson's disease is accompanied by clinical challenges, including an inability to make a definitive diagnosis at the earliest stages of the disease and difficulties in the management of symptoms at later stages. Furthermore, there are no treatments that slow the neurodegenerative process. In this Seminar, we review these complexities and challenges of Parkinson's disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging.

              In the domain of health, one important challenge is the efficient delivery of drugs in the body using non-toxic nanocarriers. Most of the existing carrier materials show poor drug loading (usually less than 5 wt% of the transported drug versus the carrier material) and/or rapid release of the proportion of the drug that is simply adsorbed (or anchored) at the external surface of the nanocarrier. In this context, porous hybrid solids, with the ability to tune their structures and porosities for better drug interactions and high loadings, are well suited to serve as nanocarriers for delivery and imaging applications. Here we show that specific non-toxic porous iron(III)-based metal-organic frameworks with engineered cores and surfaces, as well as imaging properties, function as superior nanocarriers for efficient controlled delivery of challenging antitumoural and retroviral drugs (that is, busulfan, azidothymidine triphosphate, doxorubicin or cidofovir) against cancer and AIDS. In addition to their high loadings, they also potentially associate therapeutics and diagnostics, thus opening the way for theranostics, or personalized patient treatments.
                Bookmark

                Author and article information

                Journal
                ACS Nano
                ACS Nano
                nn
                ancac3
                ACS Nano
                American Chemical Society
                1936-0851
                1936-086X
                22 April 2021
                25 May 2021
                : 15
                : 5
                : 8592-8609
                Affiliations
                []Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST , Campus UAB, 08193 Bellaterra, Barcelona, Spain
                []Institut de Biotecnologia i de Biomedicina (IBB), Universitat Autònoma de Barcelona , 08193 Bellaterra, Barcelona, Spain
                [§ ]Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Biociències, Edifici C, Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès, Spain
                []Departament de Química, Universitat Autònoma de Barcelona (UAB) , Campus UAB, 08193 Cerdanyola del Vallès, Barcelona, Spain
                []Centro de Investigacion Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) , 08193 Cerdanyola del Vallés, Spain
                [6a] #Servei de Ressonància Magnètica Nuclear, Institut de Neurociències, Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona , 08193 Cerdanyola del Vallès, Spain
                []Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Edifici Collserola Hospital Universitari Vall d’Hebron , Passeig de la Vall d’Hebron, 129, 08035 Barcelona, Spain
                []ICREA-Institució Catalana de Recerca i Estudis Avancats , 08010 Barcelona, Spain
                Author notes
                Author information
                http://orcid.org/0000-0002-1517-3612
                http://orcid.org/0000-0002-4156-0579
                http://orcid.org/0000-0002-1352-989X
                http://orcid.org/0000-0002-6844-8421
                Article
                10.1021/acsnano.1c00453
                8558863
                33885286
                b2a326a1-7879-4dd4-9a11-88651cec4926
                © 2021 American Chemical Society

                Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 17 January 2021
                : 12 April 2021
                Funding
                Funded by: Michael J. Fox Foundation for Parkinson''s Research, doi 10.13039/100000864;
                Award ID: 15291.01
                Funded by: Agencia Estatal de Investigación, doi NA;
                Award ID: SEV-2017-0706
                Funded by: European Regional Development Fund, doi 10.13039/501100008530;
                Award ID: NA
                Funded by: Ministerio de Ciencia e Innovación, doi 10.13039/501100004837;
                Award ID: RTI2018-098027-B-C22
                Funded by: Ministerio de Ciencia e Innovación, doi 10.13039/501100004837;
                Award ID: RTI2018-098027-B-C21
                Funded by: Generalitat de Catalunya, doi 10.13039/501100002809;
                Award ID: NA
                Funded by: European Cooperation in Science and Technology, doi 10.13039/501100000921;
                Award ID: CA17121
                Funded by: H2020 Research Infrastructures, doi 10.13039/100010666;
                Award ID: 777222
                Funded by: “la Caixa” Foundation, doi 10.13039/100010434;
                Award ID: 100010434 - LCF/PR/HR17/52150003
                Categories
                Article
                Custom metadata
                nn1c00453
                nn1c00453

                Nanotechnology
                neuromelanin,dopamine,parkinson’s disease,neurodegeneration,coordination polymers
                Nanotechnology
                neuromelanin, dopamine, parkinson’s disease, neurodegeneration, coordination polymers

                Comments

                Comment on this article